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Abstract 
The composition of the gut microbiota is in constant flow under the influence of factors such as the 
diet, ingested drugs, the intestinal mucosa, the immune system, and the microbiota itself. Natural 
variations in the gut microbiota can deteriorate to a state of dysbiosis when stress conditions rapidly 
decrease microbial diversity and promote the expansion of specific bacterial taxa. The mechanisms 
underlying intestinal dysbiosis often remain unclear given that combinations of natural variations and 
stress factors mediate cascades of destabilizing events. Oxidative stress, bacteriophages induction 
and the secretion of bacterial toxins can trigger rapid shifts among intestinal microbial groups 
thereby yielding dysbiosis. A multitude of diseases including inflammatory bowel diseases but also 
metabolic disorders such as obesity and diabetes type II are associated with intestinal dysbiosis. The 
characterization of the changes leading to intestinal dysbiosis and the identification of the microbial 
taxa contributing to pathological effects are essential prerequisites to better understand the impact 
of the microbiota on health and disease. 
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Introduction  
The gut microbiota can be viewed as an actual body organ contributing to the well-being of the host 
organism. The trillions of microbes colonizing the gastrointestinal tract influence local and systemic 
processes such as nutrient transformation [1], vitamin supply [2], maturation of mucosal immunity 
[3, 4], gut-to-brain communication [5], and even tumor progression [6]. Like other organs, the proper 
function of the gut microbiota relies on a stable cellular composition, which in the case of the human 
microbiota consists mainly of bacteria from the phyla Bacteroidetes, Firmicutes, Actinobacteria, and 
to a lesser extent Proteobacteria [7]. Large shifts in the ratio between these phyla or the expansion 
of new bacterial groups lead to a disease-promoting imbalance, which is often referred to as 
dysbiosis. A reduction of microbial diversity and outgrowth of Proteobacteria are cardinal features of 
dysbiosis [8, 9]. A growing number of diseases is associated with intestinal dysbiosis, which in some 
cases contributes to disease development or severity. Dysbiosis is a hallmark of inflammatory bowel 
diseases (IBD) such as ulcerative colitis and Crohn’s disease [10], but also metabolic disorders [11], 
autoimmune diseases [12], and neurological disorders [13]. Dysbiosis can trigger disease in the first 
weeks of life as observed in necrotizing enterocolitis [14], during adulthood through the promotion 
of colorectal cancer [15], or in elderly people as exemplified by Clostridium difficile-associated 
diarrhea [16].   
Unlike infectious microbes, the pathogenicity of specific intestinal bacteria cannot be established 
through the application of Koch’s Postulates given that a major fraction of the microbiota cannot be 
isolated as pure culture. Therefore, the pathogenic implication of specific microbes in a disease 
largely relies first on the identification of shifted bacterial populations based on high-throughput 
DNA sequencing of conserved 16S rRNA genes [17]. The replication of a disease through the 
transplantation of the gut microbiota from a diseased animal to a healthy one is often used in a 
second step to confirm the contribution of intestinal dysbiosis to disease. Microbiota transplantation 
demonstrated the contribution of intestinal microbes, among others, to obesity [18] and 
atherosclerosis [19] in mice. Nevertheless, despite strong evidence gained from 16S rRNA sequencing 
and microbiota transplantation, the culpability of specific bacterial groups enriched in a disease state 
often remains circumstantial. Instead of being true offenders, suspected bacteria can just be 
bystanders to real pathogens that remain below the threshold of current detection techniques. The 
extensive mutualism prevailing in the intestinal microbiota strengthens connections between 
offenders and bystanders. Bacteria producing a broad range of digestive enzymes frequently cross-
feed other bacteria harboring limited foraging abilities [20]. Increased liberation of nutrients may 
promote the parallel outgrowth of harmless and harmful bacteria. Furthermore, the borderline 
between good and evil is often blurred given that some symbiotic bacteria may become pathogenic 
when present in larger numbers in the gut. Such bacteria, referred to as pathobionts [21], may be 
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difficult to recognize when their expansion occurs simultaneously to other changes in the gut 
microbial composition. Beyond the assignment of guilt by association, the discovery of the 
mechanisms underlying the shifts of microbial groups is instrumental to understand the processes 
leading to dysbiosis. Accordingly, the identification of factors causing strong shifts in the gut 
microbiota is pivotal to devise strategies aimed at preventing intestinal dysbiosis.  
Between resilience and fragility 
Several exogenous and endogenous factors affect the microbial composition of the intestine. The 
resulting effects range from transient to long-lasting and these effects can scale from harmless to 
harmful. Often, a single factor is not sufficient to induce dysbiosis as the gut microbiota has an 
intrinsic resilience, a capacity to adapt to variations in nutrient availability and changing 
environmental conditions. The combined actions of several factors by contrast can move microbial 
groups to a tipping point, which eventually burst to vast shifts of pathological significance. The main 
factors influencing the composition of the gut microbiota are the diet, various drugs, the intestinal 
mucosa, the immune system, and the microbiota itself. Moderate shifts in microbial composition can 
then provide a window of opportunity for other aggravating factors to amplify changes in specific 
bacterial groups to the point of imbalance. Oxidative stress, bacteriophages, and bacteriocins are 
typical factors exacerbating shifts of the microbiota to the point of dysbiosis (Figure 1).     
The threshold required to trigger dysbiosis largely depends on the bacterial groups affected. Broad 
shifts in the main phyla Bacteroidetes and Firmicutes may remain without pathologic consequence, 
whereas increased amounts of marginal groups may wreak havoc. For example, Enterobacteriaceae 
normally represent a minor fraction of the gut microbiota [22]. Bacteria from the family of 
Enterobacteriaceae can expand rapidly consecutive to changes in oxidative conditions of the gut such 
as occurring during inflammation [9, 23]. Because of the pyrogenicity of Enterobacteriaceae 
lipopolysaccharide (LPS), outgrowth of this bacterial family usually intensify an ongoing inflammatory 
response. 
In addition to the main factors introduced here above, additional parameters such as temperature, 
atmospheric pressure, and oxygen partial pressure also influence the microbial composition of the 
gut. For example, the exposure of mice to a low temperature of 6°C increased intestinal Firmicutes 
levels at the cost of Bacteroidetes and the resulting cold-adapted microbiota increased energy 
expenditure [24]. The relative abundance of Firmicutes was also increased in human subjects living at 
high altitudes [25], although the impact of altitude on the microbiota may be difficult to distinguish 
from the effects of lower ambient temperatures and different dietary habits. A group of mice 
embarked on a 13-day space flight on the Space Shuttle Atlantis yielded the first data about the gut 
microbiota in micro-gravity. The analysis of microbial composition revealed only little changes at the 
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phylum level, but some variations in Clostridiales and Lactobacillales at the order level [26]. Space 
flight also caused loss of body weight and decreased water intake, meaning that these alterations 
may also account for the changes in the gut microbiota reported. 
Nutrition 
The diet is a major element affecting the intestinal microbiota. Natural variations in food intake 
cause transient changes in microbial composition, although predominant components such as meat, 
fish, and fibers have durable effects on the microbiota and leave typical signatures characterized by 
shifts in specific bacterial groups [27]. Changing food composition as well as food shortage or 
oversupply affect the gut microbiota. The absence of nutrients in the gut occurring in parenteral 
feeding increases the levels of Proteobacteria, which promote inflammation at the mucosal wall and 
eventually cause a breakdown of the epithelial barrier [28]. Excess supply of nutrients leads to 
obesity, which is associated with dysbiosis and inflammatory metabolic disorders. Obesity is 
characterized by decreased microbial diversity [29] and over-representation of Firmicutes (Figure 2) 
as observed in ob/ob mice [18, 30] and in obese humans [31, 32]. A lower ratio of Bacteroidetes to 
Firmicutes results in a higher release of LPS into the circulation [33]. Higher LPS levels contribute to a 
state of chronic low-grade inflammation occurring in obesity (Figure 2 A). In mice, elevated levels of 
circulating LPS initiate weight gain and up-regulate markers of inflammation to a similar extent as a 
high-fat diet [34]. Metabolic endotoxemia is further enhanced by increased permeability of the gut 
wall that is caused by a high-fat/high-sugar diet through increasing levels of adherent-invasive 
Escherichia coli, which infiltrates the intestinal epithelium thereby decreasing mucus thickness [35, 
36]. The diet usually is a combination of protein, fat and carbohydrates, and therefore, the isolated 
effect of each macronutrient on the microbiota in vivo is not easily determined. But diets rich in one 
or two of these types of food provide valuable clues about their respective influences. 
Proteins 
In the long term, high uptake of animal proteins, amino acids and fats increases the relative amounts 
of Bacteroides, whereas low protein and elevated carbohydrate ingestion raises Prevotella levels [37, 
38]. But short-term bursts of high-protein intake do not necessarily yield the same effects. In obese 
men, the consumption of a protein-rich diet did not affect the abundance of Bacteroides, but the 
Roseburia/Eubacterium rectale group of bacteria was reduced probably due to lower carbohydrate 
intake [39]. In rats, feeding with a high-protein diet is associated with lower contents of Clostridium 
species and Faecalibacterium prausnitzii, while Bacteroides do not increasein parallel [40]. Whereas 
the microbial changes induced by high-protein consumption are rather moderate, the changes in 
fermentation products are more evident. A high-protein diet increases the production of branched-
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chain fatty acids, but also the production of potentially toxic substances such as sulfide, ammonia 
and N-nitroso compounds [27, 39, 41]. With an excess dietary intake of protein and amino acids, also 
the synthesis of nitric oxide increases [42]. This antimicrobial product strongly influences the gut 
microbiota, and increased NO levels measured in obese patients likely contribute to the development 
of an obesity-associated microbiota [42-44]. 
Fats 
A high fat intake induces remarkable changes in the gut microbiota composition. The overall diversity 
decreases together with the relative abundance of Bacteroidetes, whereas the relative abundance of 
Firmicutes increases [45]. Even structural features such as the degree of fatty acid saturation imprint 
the microbiota. Feeding unsaturated fats to mice increased Actinobacteria, lactic acid bacteria and 
Akkermansia muciniphila creating a microbial composition that protected from weight gain and 
white adipose tissue inflammation [46]. Interestingly, feeding mice with saturated fat resulted in a 
higher production of LPS and higher activation of Toll-like receptor (TLR)-4 and TLR2 than feeding 
with unsaturated fat [46]. 
High-fat diet also influences the gut microbiota indirectly by increasing the pool of bile acids. After 
emulsification of dietary lipids, the majority of bile acids is reabsorbed in the distal ileum. Non-
absorbed bile acids strongly influence the microbial growth by creating an environment of low pH 
and strong antimicrobial activity [47]. Feeding rats with cholic acid leads to a microbial composition 
resembling the obesity pattern of low Bacteroidetes to Firmicutes ratio [48]. Considering the 
stimulatory effect of high-fat diet on bile acids in the large intestine in mice [49], bile acids likely 
contribute to the impact of high fat intake on obesity-related dysbiosis. Furthermore, bile acids are 
signaling molecules binding to the nuclear hormone farnesoid X receptor (FXR) and the G-protein-
coupled bile acid receptor TGR5. Binding to FXR not only regulates bile acid synthesis but also 
influences lipid, glucose and energy homeostasis [50]. In the liver, FXR inhibits the induction of the 
sterol regulatory element-binding protein SREBP1c, thus inhibiting lipogenesis and decreasing the 
risk of steatosis. TGR5 signaling induces the production of glucagon-like peptide (GLP)-1 in the 
intestine which improves insulin sensitivity. By increasing mitochondrial activity in brown adipose 
tissue and oxidative phosphorylation in muscle, TGR5 activation also elevates energy expenditure 
[51, 52]. Gut bacteria regulate bile acid receptor signaling by converting primary bile acids into 
secondary bile acids that show different binding affinities. Especially bacteria of the phylum 
Firmicutes have 7α-dehydroxylation activity to turn cholic and chenodeoxycholic acid into 
deoxycholic and lithocholic acids, which have a lower binding affinity for FXR, but a higher affinity for 
TGR5 [53] (Figure 2 D). 
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Fibers 
Fibers have a direct effect on the microbiota by reaching the colon due to their indigestibility and 
feeding microbial fermentation. A diet rich in plant polysaccharides promotes the growth of 
Bacteroidetes over Firmicutes [54]. Interestingly, though, a gut microbiota with an increased 
Firmicutes to Bacteroidetes ratio has a higher capacity to extract energy from the diet by providing 
more enzymes for the breakdown of dietary polysaccharides [18, 55], thereby increasing the uptake 
of monosaccharides and short chain fatty acids (SCFA) by the intestinal mucosa. This process 
maximizes nutrient utilization but in case of excess food supply also maximizes energy storage. 
Microbially-released monosaccharides are transferred to the liver via the portal vein and activate the 
carbohydrate response element-binding protein ChREBP, leading to increased transcription of several 
genes involved in de novo hepatic lipogenesis [56, 57], thus augmenting lipid transfer to fat stores in 
peripheral tissues (Figure 2 C). The increased intestinal absorption of the SCFA butyrate, acetate and 
propionate provides additional energy for diverse tissues (Figure 2 B). Butyrate is mainly used by the 
colonocytes and stimulates their proliferation and differentiation [58]. Acetate fuels lipogenesis in 
peripheral tissues, especially muscle, whereas propionate enters gluconeogenesis in the liver [58]. A 
higher production of SCFA by obesity-associated microbiota might be one factor contributing to 
higher triglyceride deposition in fat tissues as well as in the liver [59]. In addition to their caloric 
contribution SCFA activate metabolic pathways by acting as ligands to the G-protein-coupled 
receptors GPR41 and GPR43 (also known as free fatty acid receptors 3 and 2) [60, 61]. GPR41 and 
GPR43 activation is associated with adipose tissue expansion and inflammatory processes, although 
the outcome of this activation as being protective or causative remains unclear (as reviewed in [62]). 
Activation of GPR41 and GPR43 also elevates leptin levels in adipocytes, which results in increased 
insulin sensitivity and higher satiety [63, 64]. GPR43 signaling in intestinal L-cells increases production 
of GLP-1 that improves glucose tolerance [65]. Acetate and propionate are the main ligands 
activating GPR43 in adipose tissue and immune cells as butyrate mainly serves as energy source for 
colonocytes and relatively small amounts reach the periphery [66]. In dysbiosis related to obesity, 
SCFA profiles change consecutive to decrease in the ratio between Bacteroidetes, producing high 
amounts of acetate and propionate, and Firmicutes, mainly producing butyrate [67]. Therefore, 
decreased acetate and propionate production by the microbiota likely reduces GPR43 signaling.  
The question raises whether a balanced microbiota can be restored through prebiotic and probiotic 
supplementation. Prebiotics directly modulate the microbiota and entail reduced gut permeability 
and endotoxemia, thus reducing inflammation [47, 68, 69]. These changes are linked to higher levels 
of GLP-2 which reduces gut permeability [69]. An intake of the prebiotic oligofructose shifts the 
composition of the gut microbiota towards a thin pattern by increasing Bacteroidetes and reducing 
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Firmicutes in ob/ob mice and in rats genetically prone to develop obesity and insulin resistance [70, 
71]. Probiotics that induce the secretion or lower the suppression of angiopoietin-like factor IV 
(ANGPTL4, also known as fasting-induced adipose factor) have a beneficial effect on the lipid 
metabolism in adipocytes. ANGPTL4 inhibits lipoprotein lipase, which hydrolyses triglycerides from 
lipoproteins for the fatty acid uptake into the cell. Interestingly, germ-free mice deficient in ANGPTL4 
lose their protection from diet-induced obesity [72]. Supplementation of mice with the probiotic 
Lactobacillus paracasei increases circulating levels of ANGPTL4 and reduces body fat [73] (Figure 2 C). 
Akkermansia muciniphila is another species that proved to reduce obesity when supplemented to 
mice [74, 75]. While this species might cause increased severity in colitis models [76, 77], it has a 
protective effect in obese mice by thickening the mucus layer, thereby decreasing gut permeability, 
reducing endotoxemia and preventing inflammation [75] (Figure 2 A). 
Carbohydrates 
The processing of complex plant polysaccharides, such as pectins, xylans and fructans, require a 
battery of endo- and exoglycosidases featuring activities capable of releasing monosaccharides such 
as rhamnose, galacturonic acid, arabinose, xylose, fructose and glucose [78]. By contrast, the 
utilization of intestinal mucin glycans requires different activities consisting of galactosidases, N-
acetylglucosaminidases, N-acetylgalactosaminidases, fucosidases and sialidases. The structural 
differences between dietary carbohydrates and intestinal glycans and the corresponding need for 
different processing machineries have pushed bacteria to specialize for the utilization of limited 
subsets of carbohydrates. The processing of complex carbohydrates often relies on cooperative 
actions between distinct bacterial taxa. In addition to enabling mutualistic interactions, the cleavage 
of complex carbohydrates and release of monosaccharides in the gut lumen also generates 
opportunities for bacteria, which lack carbohydrate-processing enzymes. For example, E. coli does 
not express any glycosidase capable of degrading complex carbohydrates, but it is an avid consumer 
of the monosaccharides N-acetylglucosamine, N-acetylneuraminic acid (Neu5Ac) and fucose [79]. 
Accordingly, intestinal E. coli and other Enterobacteriaceae respond to the presence of specific 
monosaccharides by increasing proliferation and changing the expression of virulence factors [80, 
81]. 
The capacity to cleave sialic acid, such as Neu5Ac and N-glycolylneuraminic acid (Neu5Gc), is 
restricted to a limited number of bacterial taxa [82]. Nan gene clusters encoding sialidases, 
transporters and catabolytic enzymes enable the release of sialic acid from intestinal glycans and its 
utilization as carbon source. Some Bacteroides species, such as Bacteroides fragilis, express fully 
operational nan clusters, whereas others, such as Bacteroides thetaiotaomicron [83] only express 
sialidases but lack transporters mediating the uptake of free sialic acid. Sialic acid liberated in this 
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way is accessed by other bacteria that express transporters enabling the uptake of the sugar. This 
type of cross-feeding is a common mechanism prevailing in the intestinal environment. 
Monosaccharides released from intestinal glycans can therefore be utilized by bacteria devoid of 
glycosidases and mediate a strong proliferating response thereby leading to dysbiosis. Antibiotic 
treatment has been shown to disturb microbiota and lead to increased liberation of sialic acid, which 
fuels the expansion of the pathogens Salmonella enterica serovar Typhimurium and Clostridium 
difficile in a mouse model [84]. Similarly, the outgrowth of E. coli and exacerbation of intestinal 
inflammation occurring after dextran sulfate sodium ingestion was shown to depend on the release 
of sialic acid from intestinal 2,3-linked sialylated glycans [85]. As mentioned in the introduction to 
this review, the intricate interactions between bacterial taxa ranging from mutualistic to parasitic 
networks complicate the identification of the mechanisms underlying dysbiosis. 
Drugs 
Oral administration is the most frequently applied route of uptake for drugs. The convenience of this 
path enables the regular uptake of drugs without medical intervention, increasing the exposure of 
the gut microbiota to drugs and thereby promoting dysbiosis.  
Non-steroidal anti-inflammatory drugs 
Conventional non-steroidal anti-inflammatory drugs, such as aspirin, ibuprofen and naproxen, affect 
the intestinal microbial composition when taken daily over months, as shown by increased 
abundance of Bacteroidaceae and Enterobacteriaceae [86]. Because non-steroidal anti-inflammatory 
drugs cause stomach ulcers, proton-pump inhibitors are often prescribed in combination to alleviate 
these side effects on the gastric and small intestinal mucosa. Proton-pump inhibitors themselves 
have been reported to alter the gut microbiota, which contributes to increased risk for C. difficile-
associated diarrhea [87] and hepatic encephalopathy in cirrhotic patients [88]. The impact of drugs 
on intestinal microbes underlines the confounding importance of medications when associating 
diseases with intestinal dysbiosis. For example, the hepatic gluconeogenesis inhibitor metformin is a 
standard medication used in the treatment of type 2 diabetes. As shown recently, the uptake of 
metformin affects the composition of the gut microbiota by elevating E. coli levels [89]. Accordingly, 
it is essential to take in account the impact of mediations on intestinal microbes when addressing 
possible correlations between changes in the gut microbiota in chronic disorders.   
Antibiotics 
Through their antibacterial activity antibiotic drugs have an intrinsic potential in promoting intestinal 
dysbiosis. Most orally administered antibiotics will alter the gut microbiota, albeit transiently for the 
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duration of treatment. Some antibiotics however induce long-lasting changes in the gut microbiota. 
Whereas several antibiotics, such as amoxicillin, do not have any significant long-term impact on the 
gut microbiota, treatment of children with macrolide antibiotics lead to long-lasting decrease in 
Firmicutes and Actinobacteria with concomitant increase in Bacteroidetes and Proteobacteria [90]. 
Similarly, treatment of adults with ciprofloxacin decreases gut microbial diversity transiently but also 
leaves a long-lasting signature characterized by increased abundance of Gram-positive aerobes [91]. 
Repeated exposure to antibiotics can destabilize the gut microbiota and promote the outgrowth of 
antibiotic-resistant pathogenic bacteria, as observed through the development of C. difficile-
associated diarrhea in elderly people [92]. In addition to their expected antibiotic effects, some 
antibiotic drugs also exert an eubiotic action [93] by promoting the expansion of beneficial bacteria 
through the suppression of pathobionts. Such an eubiotic effect is typical for rifaximin, which 
contributes to increasing the gut microbial diversity in IBD patients [94] and also improve symptoms 
of irritable bowel syndrome [95]. 
Microbial regulation of drugs 
As outlined here above, several drugs affect the gut microbiota. The reverse is true, too. Intestinal 
bacteria can metabolize drugs and thereby modify their bioavailability to the host [96]. Just to name 
few examples, the cholesterol-lowering drug simvastatin [97] and the glucocorticoid agonist 
prednisolone [98] are modified through multiple bacterially encoded enzymes present in the gut. The 
topoisomerase I inhibitor irinotecan applied in cancer chemotherapy is inactivated by 
glucuronidation in the liver. This modification is reversed in the gut through the action of bacterial 
glucuronidases, which re-activate the drug and increase intestinal toxicity [99]. Beyond their 
interactions with the gut microbiota, several drugs also affect the intestinal mucosa and its barrier 
function [100]. The complex interplay between drugs, the microbiota, the intestinal mucosa, and the 
immune system underline the importance of a comprehensive approach when unravelling the 
mechanisms underlying intestinal dysbiosis.   
Intestinal mucosa 
Mucins 
The gastrointestinal tract is lined with mucus secreted by goblet cells, thereby protecting the 
epithelium from a direct contact with the microbiota. In addition to building a physical barrier, the 
intestinal mucus is a source of nutrients for intestinal bacteria that can liberate carbohydrates from 
the glycan chains of mucins. Several bacterial groups, including for example Akkermansia muciniphila 
and Bacteroides thetaiotaomicron, express carbohydrate hydrolases as part of polysaccharide-
utilization loci, which confer the ability to extract and metabolize carbohydrates from the intestinal 
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mucus. The composition and thickness of this mucus varies along the intestinal tract, being thin and 
patchy in the ileum, but thick and stratified in the colon where the bulk of the microbiota resides. 
Glycoproteins of the mucin family are the main constituents of the intestinal mucus. Mucins carry 
dense arrays of O-linked glycan chains featuring fucosylated and sialylated structures. The 
glycosylation pattern of mucins varies along the intestinal segments, with fucosylation being 
prominent in the ileum and decreasing in the colon whereas the extent of sialylation increases from 
the ileum to the distal colon [101]. The distribution of mucins also varies along the gastrointestinal 
tract. Especially the gel-forming mucins MUC2, MUC5AC, MUC5B and MUC6, which represent the 
main constituents of the intestinal mucus in humans, are differentially expressed, with MUC5AC and 
MUC6 being mainly found in the stomach mucus and MUC2 being mainly found in the colon [102]. 
The human colon secretes about 200 ml of mucus daily. This amount is largely controlled through the 
transcriptional regulation of MUC2 expression. Multiple factors including the bacterial products LPS 
and lipoteichoic acid, cytokines such as tumor necrosis factor (TNF)-, interleukin (IL)-4 and IL-13, 
and hormones such as vasoactive intestinal peptide increase MUC2 transcription [103, 104]. Mucin 
glycosylation also changes under the influence of hormones and cytokines produced during 
inflammation [105]. Bacterial LPS and the cytokine IL-23 induce the expression of the 
fucosyltransferase FUT2 in the small intestine, which increases the fucosylation of intestinal mucins 
[81, 106]. The resulting changes in glycosylation alter the supply of carbohydrates available to 
bacteria utilizing mucin glycans as carbon source, thereby changing the microbiota composition. 
Increased availability of specific carbohydrates also affects the expression of virulence factors by 
pathogens, as shown by the repression of LEE virulence genes by enterohaemorrhagic E. coli 
mediated by increased concentration of free fucose in the colon [80]. 
Glycans 
The ability to extract carbohydrates from mucin glycans is concentrated in bacterial groups, which 
express a vast set of hydrolase enzymes and transporters enabling the utilization of monosaccharides 
as carbon sources. Among the bacterial phyla of the human gut, Bacteroidetes express the largest 
carbohydrate-fermenting machineries. Several Firmicutes, such as Ruminococcus intestinalis, R. 
gnavus and R. flavefaciens also express more than 100 carbohydrate-degrading enzymes per genome 
and are capable of digesting mucin glycans [107]. By contrast, members of Proteobacteria, such as 
Enterobacteriaceae have very limited ability to degrade intestinal mucins. Among Actinobacteria, 
several Bifidobacterium spp. are specialized at fermenting complex fucosylated oligosaccharides 
[108], which explains their prominence in the gut of breastfed infants. Akkermansia muciniphila, a 
member of the Verrucomicrobiota phylum, commonly found in the gut microbiota is another 
microbe specialized in the utilization of intestinal mucins as carbon source [109]. Carbohydrate-
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fermenting machineries are decisive for the maintenance of specific bacterial groups in the gut, as 
demonstrated by the dramatic drop in fitness of a mutant B. thetaiotaomicron lacking 
polysaccharide-utilization loci involved in the metabolism of mucin O-glycans [110]. 
Adhesion to intestinal glycans 
Bacterial adhesion is another parameter influenced by variations of the carbohydrate landscape in 
the intestinal mucosa. Several bacteria express adhesins, fimbriae and pili carrying carbohydrate-
binding domains. Lactobacilli for example rely on a family of mucus-binding proteins to colonize the 
gastrointestinal tract [111]. In addition to commensals, pathogenic bacteria such as Campylobacter 
jejuni express adhesins that bind to fucosylated epitopes, such as blood group antigens H2, Lewis-b, 
Lewis-y and Lewis-x [112], which are exposed on intestinal mucins and epithelial cells. Changes in the 
density of fucosylated glycans or the passage of soluble fucosylated molecules, such as milk 
oligosaccharides [113] in the intestinal lumen alter the adhesion of C. jejuni to the intestinal mucosa 
and force its elimination from the intestinal tract. The importance of intestinal carbohydrates in 
regulating the binding of microbes and even controlling their tissue and animal tropism is illustrated 
by the binding specificity of E. coli K99. This strain expresses fimbriae, which recognize gangliosides 
terminated with 2,3-linked Neu5Gc [114]. This ligand is richly expressed in the intestinal mucosa of 
young piglets, which are the common targets of E. coli K99, whereas adult pigs, expressing 
gangliosides terminated with 2,3-linked Neu5Ac, are resistant to E. coli K99 infection. The role of 
glycosylation in conferring binding to the intestinal mucosa is not limited to bacteria. Several 
bacterial toxins of type AB5, such as cholera, shiga and pertussis toxins, enter cells after binding to 
surface carbohydrates. The SubAB toxin secreted by Shiga toxigenic E. coli for example binds to 
Neu5Gc-containing glycans on human gut epithelial cells [115]. Human cells cannot synthesize 
Neu5Gc, but this carbohydrate is incorporated on human glycans after ingestion of food rich in 
Neu5Gc such as red meat [116]. The modulation of SubAB susceptibility through the assimilation of 
dietary Neu5Gc shows that nutrients affect the composition of the intestinal mucosa and thereby the 
risk for disease. Changes in intestinal glycosylation can also alter the local distribution of 
bacteriophages, which express carbohydrate-binding proteins [117]. In addition to the diet, genetic 
polymorphisms related to intestinal glycans also have profound effects on the composition of the gut 
microbiota. For example, hypomorphic alleles leading to differential expression of the 1-2 
fucosyltransferase FUT2 enzyme confer susceptibility to Crohn’s disease [118]. Finally, the microbiota 
itself also regulates intestinal mucin secretion and glycosylation, as outlined by the different 
glycosylation of MUC2 produced in conventionally raised mice and germ-free mice [119]. 
Immunity 
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The immune system enables a symbiotic relationship with commensal microbiota by maintaining a 
non-inflammatory homeostasis. This state of tolerance relies on multiple mechanisms such as a 
physical mucus barrier minimizing the contact to the epithelium, and the secretion of antimicrobial 
proteins and immunoglobulin A [120]. Despite the absence of inflammation, the immune system 
constantly senses and contains the gut microbiota. Each component of the immune system exerts 
pressure on portions of the gut microbiota (Figure 3).  For example, the absence of immunoglobulin 
A yields a strong expansion of anaerobic bacteria, especially mucosa-adherent segmented 
filamentous bacteria (SFB) of the phylum Firmicutes [121] (Figure 3 D). Components of the innate 
immune system, such as TLR, nucleotide oligomerization domain (NOD) proteins, and the 
inflammasome also affect the bacterial composition of the gut. 
Inflammasome 
Inactivation of the NOD-like receptor family pyrin domain containing 6 (NLRP6) protein, which is a 
component of the inflammasome complex, results in the expansion of Prevotella spp. and TM7 
bacteria [122] (Figure 3 A). These microbial changes render mice more susceptible to dextran sulfate 
sodium-induced colitis and intestinal infections. The higher susceptibility is enhanced by impaired 
mucus secretion from goblet cells in NLRP6-deficient mice leading to a reduced mucus layer [123]. 
Interestingly, mucus reduction is directly caused by the altered microbiota and not by NLRP6-
deficiency as it is transferable to wildtype mice by co-housing. NLRP6 activation mediates the 
secretion of IL-18 via caspase-1. The role of IL-18 in intestinal homeostasis is still controversial. It acts 
as a pro-inflammatory cytokine that suppresses mucin production by inhibiting the maturation of 
goblet cells, thus promoting colitis as typically seen in ulcerative colitis [124, 125]. In contrast, IL-18 
also down-regulates IL-22-binding protein, which enables IL-22 to induce intestinal tissue repair and 
expression of antimicrobial peptides [126, 127].  
Innate Immunity 
TLR5, the pattern recognition receptor that recognizes flagellin on the epithelial surface, plays a 
major role in maintaining the balance of the microbiota. Apart from stimulating IL-8 and TNFα 
secretion in epithelial cells and monocytes [128, 129], TLR5 signaling also induces the expression of 
IL-22 and IL-17 in the mucosa [130]. Upon inactivation of TLR5, dysbiosis with altered abundances of 
more than 100 phylotypes develops (Figure 3 B), thereby promoting several features of the 
metabolic syndrome including obesity and insulin resistance [131]. Microbial transplantation from 
TLR5-deficient mice to wild type mice confirmed the causative role of dysbiosis in the development 
of the metabolic syndrome. TLR5 deficiency can also cause a bloom in Enterobacteriaceae, especially 
E. coli, which results in spontaneous colitis [132, 133].  
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The NOD2 receptor, expressed in monocytes and Paneth cells [134], regulates commensal gut 
community by restricting the number of bacteria and the colonization by pathogens, especially in the 
terminal ileum [135]. Crohn’s disease is associated with polymorphisms in the NOD2 gene [136, 137]. 
Defects in the NOD2 receptor lower the expression of α-defensin in Paneth cells [138] (Figure 3 C). 
Loss of α-defensin increases the ratio of Firmicutes to Bacteroidetes. In line with this result, 
expression of human α-defensin in mice decreases the abundance of SFB, which belong to the 
phylum Firmicutes, and decreases the numbers of IL-17-producing Th17 cells in the lamina propria 
[136]. In the colon, SFB are located close to the epithelium [139] and are instrumental in initiating 
antimicrobial defense, for example by promoting the development of Th17 cells. The expression of 
IL-17 in turn increases α-defensin secretion, which inhibits the expansion of SFB. Accordingly, 
deletion of the IL-17 receptor leads to a similar dysbiosis as seen with defects in the NOD2 receptor 
[140]. SFB also induce the development of regulatory T (Treg) cells [141]. Treg cells maintain a 
mutualistic interaction with the microbiota by secreting anti-inflammatory IL-10 and transforming 
growth factor- (TGF-β) [142]. IL-10 has a profound effect on the microbiota composition. Mice 
deficient in IL-10 have increased numbers of Verrucomicrobia, Bacteroidetes, and Proteobacteria as 
characterized by a 100-fold increase in E. coli [143]. These bacterial shifts are accompanied by 
inflammation in the caecum and colon [144]. The beneficial influence of probiotics like lactobacilli 
and bifidobacteria comprises the ability to induce Treg cells and thereby IL-10 secretion [145]. Also 
Faecalibacterium prausnitzii, which is less abundant in Crohn’s disease patients than in healthy 
subjects, exerts its anti-inflammatory effects partially via the elevation of IL-10 production [146]. 
TGF-β also suppresses an inflammatory response and mediates immune tolerance. Its production is 
not limited to Treg cells, but occurs in various cells of the intestinal mucosa including intestinal 
dendritic cells (DC) [147]. As IL-10, TGF-β maintains homeostasis of the gut microbiota by regulating 
microbial composition. In absence of DC-specific TGF-β signaling, members of Enterobacteriaceae, 
especially E. coli, are significantly enriched [148]. The probiotic Clostridium butyricum is able to 
induce TGF-β signaling in DC, which in turn induces Treg cell generation [147]. 
Immune modulation by dysbiosis 
While a dysbiotic gut community is a hallmark of several inflammatory diseases, dysbiosis in turn also 
triggers mechanisms that unbalance the intestinal homeostasis and cause inflammation. The 
translocation of bacteria across the gut epithelium increases in dysbiosis [149]. Small numbers of 
translocated commensal bacteria, as they occur in a healthy human gut, are removed by the action 
of Th1 and Th17 cells that are particularly induced by polysaccharides of Bacteroides spp. [150] and 
mucosa-adherent SFB [151]. But high numbers of invading bacteria continuously activate TLRs and 
elicit an overexpression of pro-inflammatory cytokines, which damage the gut epithelium and lead to 
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chronic intestinal inflammation [152]. Chronic inflammation is associated with several metabolic 
disorders such as autoimmune diabetes. Strikingly, higher SFB levels as found in MyD88-deficient 
mice protect mice of a diabetic genotype from developing the disease indicating that microbiota 
exert both inhibiting and promoting effects [153-156].  
A disturbed microbiota also affects the maturation of the innate immune system as gut bacteria per 
se are a driving force in that process. Without microbiota, the function of neutrophils and DC is 
impaired, displaying reduced killing of pathogens and reduced secretion of type I interferons (IFN-I) 
and IL-15, respectively [157, 158]. Already the development of myeloid cells in the bone marrow is 
delayed in absence of microbiota [159]. This delay impairs the clearance of systemic infections and 
increases the susceptibility to allergies [158-160]. Disturbances in the microbial community can have 
a similar detrimental effect. Mice treated with antibiotics during early development have an 
increased production of IL-4 and lower numbers of Treg cells and, later in life, are more susceptible 
to colitis and airway hyper-reactivity [161]. Persistent alterations caused by antibiotic treatment in 
early human life correlate with IBD, asthma and atopic dermatitis in later life [162-164]. The state of 
non-inflammatory homeostasis in the gut can be shaken up by both the host immune system and the 
intestinal microbiota. Imbalance of their interplay increases the risk for immune-related diseases. 
Oxidative stress  
Oxidative stress occurring during inflammation is a factor amplifying dysbiosis by strongly decreasing 
the microbial diversity in the gut and by promoting the outgrowth of specific bacterial taxa. 
Leukocyte infiltration is a hallmark of intestinal inflammation, which is accompanied by generation of 
reactive oxygen and nitrogen species. The resulting oxidative stress exerts a manifest antimicrobial 
action, especially targeting strictly anaerobic bacteria that are susceptible to oxygen intoxication. The 
amount of microbes drops dramatically upon onset of inflammation, leading to the depletion of close 
to 80% of the microbiota in some models [9]. In addition to killing anaerobic residents, reactive 
oxygen species also promote the selective growth of bacterial groups through nitrate and 
tetrathionate respiration [165]. Sulfate-reducing bacteria are widespread in the gut microbiota [166] 
and produce hydrogen sulfide (H2S) and thiosulfate (S2O32-), which can be oxidized to tetrathionate 
(S4O62-) in the presence of reactive oxygen species. Elevation of tetrathionate in the gut promotes the 
growth of certain Enterobacteriaceae including Salmonella and Citrobacter, which can use 
tetrathionate as a respiratory electron acceptor [167]. The reaction of nitric oxide with superoxide 
anion yields peroxynitrile (ONOO-), which is a strong reactive product of the respiratory burst of 
macrophages [168]. Peroxynitrile isomerizes to nitrate (NO3-), which can be utilized by E. coli through 
nitrate respiration, thereby favoring its growth during inflammation. The importance of nitric oxide 
and nitrate respiration in conferring a growth advantage to E. coli was confirmed by inhibiting the 
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nitric oxide synthase iNOS with aminoguanine hydrochloride during colitis in a mouse model [169]. 
The ability to utilize nitrate as respiratory electron acceptor is a factor contributing to dysbiosis. 
Interestingly, nitrate respiration can be boosted in S. enterica ser. Typhimurium through expression 
of the bacteriophage-transmitted virulence gene sopE, which stimulates iNOS expression in the 
intestinal mucosa [170]. This example shows that oxidative stress and bacteriophages can synergize 
to promote dysbiosis.     
Bacteriophages 
The bacteriophage fraction of the gut microbiota is like the dark matter of the universe. 
Bacteriophages probably play a major role in the homeostasis of the gut microbiota, but their true 
contribution is difficult to establish given the challenging identification of bacteriophage signatures 
within microbial genomes. Unlike bacteria identified by 16S rRNA sequencing, bacteriophage 
genomes lack conserved regions enabling their simple classification. A recent metagenomics survey 
aimed at identifying bacteriophages in the human gut found 44 bacteriophage groups, of which 
about a fifth was found in the majority of the samples analyzed. A group of 23 bacteriophages, 
mainly representing members of the order of Caudovirales and family of Microviridae, was even 
found in more than 50% of healthy individuals [171]. Because lysogenic bacteriophages dominate the 
human gut [172, 173], phage sequences are mainly embedded as prophage DNA in bacterial 
chromosomes. The difficulty in distinguishing viral open reading frames from bacterially-encoded 
genes likely results in the under-estimation of the bacteriophage diversity in the gut. The newly 
discovered adaptive immune system of bacteria consisting of captured foreign DNA fragments into 
bacterial chromosomes is a valuable source of information to recognize bacteriophage infections. 
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) represent an archive of 
past infections in bacterial genomes and their sequencing reveals the history of phages encountered 
by bacterial hosts. The analysis of CRISPRs in the gut microbiota from 124 European subjects revealed 
close to 1000 bacteriophages, of which 78% were shared by at least two individuals [173]. The 
sequences of the DNA spacers flanking phage fragments enabled the assignment of 11 bacterial 
hosts for 31 assembled phage contigs, showing that 14 of these phages target bacteria of the families 
of Bacteroides and Parabacteroides [173]. The analysis of bacteriophage occurrence in IBD confirmed 
the diversity of bacteriophages in ulcerative colitis and Crohn’s disease. Bacteriophage richness, as 
defined by the number of taxa per sample, was increased in these diseases, whereas bacterial 
richness was concomitantly decreased [174]. Whether bacteriophages indeed contribute to disease 
development remains however unclear at this stage. 
Environmental stress imposed by inflammation and antibiotics can activate the lytic cycle of 
integrated prophages, thereby leading to a rapid elimination of bacterial hosts. In addition to a 
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sudden change in the abundance of some bacterial taxa, the lytic action of bacteriophages liberates 
intracellular toxins [175] as well as cell wall fragments, lipids and nucleic acids, which are recognized 
as pathogen-associated molecular patterns activating innate immunity. The interlaced stimulation of 
the immune response and activation of phage lytic cycles fuel each other, which amplifies dysbiosis 
occurring during gut inflammation. Beyond their impact on the gut microbiota consecutive to 
environmental challenges, phages also contribute to the long-term shape of the gut microbiome 
through their action as vectors for the horizontal transfer of resistance genes. 
The intestinal mucosa is another factor influencing the interactions between bacteriophages and 
their bacterial hosts. Several bacteriophages express proteins featuring C-type lectin folds and 
immunoglobulin-like domains [176], which interact with the heavily O-glycosylated mucin MUC2 
[177, 178] in the colon. For example, the highly antigenic outer capsid protein of the bacteriophage 
T4 preferentially binds to O-glycan chains found on mucins. Adhesion to intestinal glycoproteins 
increases the bacteriophage density in the mucus layer, which acts as a protective barrier for the 
host by killing mucus-penetrating bacteria [117]. Changes in mucosal glycosylation, as occurring 
during intestinal inflammation [81], can alter the local abundance of bacteriophages and thereby 
affect the proliferation or eradication of specific bacterial groups and thereby promote dysbiosis. 
Bacteriocins 
The prevalent competition for nutrients in the colon drives the development of strategies enabling 
bacteria to outcompete or eliminate their competitors. One of these strategies is illustrated by the 
secretion of bacteriocins, which are toxic proteins and peptides targeting related taxa competing for 
the same resources. The family of bacteriocin covers colicins in E. coli, pyocins in Pseudomonas, 
pesticins in Pasteurella pestis and Yersinia pestis among others [179]. Bacteriocins also include 
microcins, which are short antimicrobial peptides [180]. The bacterial strains producing bacteriocins 
also express immunity proteins that protect them against the toxic effect of their own bacteriocins. 
Most bacteriocins kill by forming pores in membranes or by cleaving nucleic acids. Stress conditions 
such as oxidative and genotoxic stress induce the expression of bacteriocins [181], thus underlining 
the significance of bacteriocins in the mechanisms amplifying shifts in bacterial composition during 
inflammation-related oxidative stress. The expression of microcins in Enterobacteriaceae is also 
induced in conditions of nutrient shortage. For example, E. coli Nissle 1917 secrete microcins [182] 
preventing the growth of other E. coli strains when iron availability is limited, for example during 
inflammation. In fact, supplementation of mice with iron during intestinal inflammation decreases 
the production of microcins, which results in the proliferation of competing E. coli thereby restricting 
the growth of E. coli Nissle 1917 [183]. Of note, E. coli Nissle 1917 is the only probiotic recommended 
by the European Crohn’s and Colitis Organization as an alternative to the non-steroid anti-
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inflammatory drug mesalazine in the treatment of ulcerative colitis, as underlined in recent meta-
analyses [184, 185]. Niche competition in the intestine has also been described for Gram-positive 
bacteria, such as members of the Enterococcus genus. Enterococcus faecalis produces a bacteriocin 
transmitted through plasmid conjugation, which disrupts the proliferation of other enterococci [186]. 
Beyond their contribution in the development of dysbiosis during inflammation, bacteriocins 
represent interesting candidate drugs aiming at the selective inhibition of pathogenic bacteria 
resistant to conventional antibiotics, such as C. difficile [187] and methicillin-resistant Staphylococcus 
aureus [188].             
Dysbiosis and disease 
As outlined in the previous sections of this review, the mechanisms destabilizing the gut microbiota 
are plentiful. Equally numerous are the diseases, which intestinal dysbiosis influences the course and 
severity. Typical examples including IBD [189], type 1 diabetes [190], celiac disease [191], and 
cardiovascular disorders [192] have been covered extensively in other reviews. We here focus our 
discussion on three diseases affecting human beings at different stages of life, namely necrotizing 
enterocolitis in newborns, colorectal cancer in adults, and C. difficile-associated diarrhea in elderly 
people.     
Necrotizing enterocolitis 
Necrotizing enterocolitis is a fulminant gut inflammation that is most frequent in premature 
newborns, affecting up to 10% of infants with a birthweight below 1500 g. Mortality can be as high as 
30% [14]. The first signs of necrotizing enterocolitis are usually a distended abdomen and bloody 
stool. As reflected by these unspecific symptoms, the pathogenesis of necrotizing enterocolitis is 
unclear. Several risk factors, including enteral feeding, bottle-feeding, immature immunity, and 
altered microbiota increase the incidence of necrotizing enterocolitis. Conversely, breastfeeding 
decreases the occurrence of necrotizing enterocolitis by at least six fold in comparison with bottle-
feeding [193]. This large impact has led the American Academy of Pediatrics to recommend feeding 
premature babies with breast milk immediately after birth [194]. The molecular nature of the 
protection conferred by breast milk remains however elusive. Breast milk lactoferrin and 
immunoglobulins have been investigated as possible protective compounds but found to be 
ineffective at decreasing the incidence and severity of necrotizing enterocolitis [195]. Given that 
pasteurized breast milk is as protective as fresh milk, heat-resistant compounds such as milk 
oligosaccharides are likely to contribute to the protective effect. Oral supplementation with the 
prebiotics galacto-oligosaccharide, fructo-oligosaccharide and lactulose nevertheless did not 
influence the course of necrotizing enterocolitis, although they mediated a relative increase of 
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bifidobacteria and lactobacilli levels in the treated newborns [196]. Supplementation with the 
probiotic Bifidobacterium breve BBG-001 also failed to improve the survival rate of infants with 
necrotizing enterocolitis [197]. Despite the unclear etiology, several findings converge towards a 
central role of the gut microbiota in triggering necrotizing enterocolitis. A sudden rise of 
Proteobacteria and a concomitant fall of Firmicutes levels has been found to precede the onset of 
the disease. Enterobacteriaceae, which are prominent members of the Proteobacteria phylum, 
express hexacylated LPS that are strong pyrogens and induce a robust inflammatory response 
mediated through TLR4 signaling. The mechanisms underlying the increase in Proteobacteria remain 
unclear. Is the proliferation of facultative anaerobic bacteria such as Enterobacteriaceae facilitated 
by the presence of oxygen in the newborn colon? As outlined in the present review, multiple 
mechanisms account for the development of dysbiosis. Given the resilience of the gut microbiota in 
response to changes, the occurrence of dysbiosis in necrotizing enterocolitis is likely the result of a 
chain of events combining an inadequate supply of protective nutrients and prebiotics, an immature 
immune system and an insufficient secretion of intestinal mucus.   
Colorectal cancer 
Dysbiosis of the gut microbiota can entail severe consequences. It is a primary driving force of 
inflammation and is unequivocally linked to the development of colorectal cancer [15]. Around 15% 
of all cases of cancer are linked to a viral or bacterial infection [198]. Infectious agents, especially 
viruses, can initiate or enhance tumor growth by inducing chronic inflammation, transferring active 
oncogenes into the host genome or by promoting immunosuppression. Microbial pathogens can 
influence tumorigenesis either directly by substances that lead to DNA damage, such as nitric oxide 
or reactive oxygen species, or indirectly by creating a pro-inflammatory microenvironment [199]. For 
example, an infection with oncogenic Helicobacter pylori results in chronic inflammation with 
dysregulated β-catenin signaling in epithelial cells fostering malignant transformations in the 
stomach [200]. Also in the colon, risk for adenocarcinoma is increased with Helicobacter pylori 
infection [201]. Especially strains positive for the virulence factor cytotoxin-associated gene A (CagA) 
are linked to carcinoma development [201, 202]. But what role do members of the commensal 
microbiota play and which shifts in the microbiota are linked to tumor development? The microbiota 
composition is significantly different in colorectal cancer patients compared to healthy individuals. 
Colorectal cancer is associated with increased abundance of the phyla Firmicutes and Fusobacteria 
[203, 204]. Strikingly, Fusobacteria constitute around 10% of the gut bacteria in colorectal cancer 
patients, but less than 0.1% in healthy individuals. These shifts in the microbiota can create a gut 
community with higher genotoxic and carcinogenic potential. Fusobacterium nucleatum, a species 
highly abundant in tumor tissues [205], expresses the virulence factor Fusobacterium adhesin A 
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(FadA) [206]. This adhesion molecule increases epithelial permeability and invasion of microbes into 
the cells [207]. FadA also activates proliferation and growth of normal and adenoma cells via β-
catenin signaling [208]. 
A dysbiotic gut community may trigger tumor development via innate immune responses, more 
precisely by activation of MyD88. In a mouse model of spontaneous intestinal tumorigenesis, 
signaling through MyD88 was necessary for extensive tumor growth [209]. By contrast, mice with 
chemically induced colitis had more intestinal tumors without MyD88 signaling [210]. The second 
branch of MyD88 signaling, via inflammasome-derived IL-18, might explain the contradictory effects 
of MyD88 signaling in the different cancer models. The lack of protective and tissue-repairing IL-18 
and the resulting inability to heal chemically-induced epithelial damages might enhance the mutation 
rate and adenoma formation in epithelial cells, thereby outbalancing the protective effect of MyD88 
deficiency [211-214]. In contrast to MyD88, TLR4 signaling showed consistent tumor-promoting 
effects in several cancer models [215]. TLR4 signaling is increased in colorectal cancer patients [216, 
217]. The LPS-mediated increase in prostaglandin E2 that activates epidermal growth factor 
receptors [215, 218, 219] is needed to promote proliferation of epithelial cells and their protection 
against apoptosis. However, the same mechanism might also promote the formation and growth of 
colorectal tumors when LPS stimulation exceeds the normal level and elicits chronic TLR4 activation 
[219, 220]. Interestingly, an increased inflammatory state in obese individuals correlates with higher 
risk of colorectal cancer [221].  Elevated TLR4 activation is also observed in IBD [222]. The two main 
forms of IBD, ulcerative colitis and Crohn’s disease, are risk factors for colitis-associated colorectal 
cancer [223, 224]. The TLR/MyD88 pathway is in fact of major importance for the initiation of colitis-
associated cancer. In absence of MyD88, mice presenting spontaneous colitis induced by IL-10-
deficiency fail to develop carcinogen-induced tumors [225]. 
Specific shifts in the microbiota facilitate the formation of colorectal cancer. High consumption of red 
meat, a rich source of thiol-containing amino acids, increases the number of sulfate-reducing 
bacteria (e.g. Desulfovibrio spp., Desulfobacter spp.) in the intestine. These bacteria generate H2S 
which decreases mucus formation, inhibits methylation of DNA and increases the generation of 
reactive oxygen species [226]. Also single bacterial species can contribute to tumor growth. 
Enterotoxigenic Bacteroides fragilis stimulates cell proliferation via increased β-catenin nuclear 
signaling [227] and damages DNA through reactive oxygen species [228]. Colitogenic E. coli 
overrepresented in the context of inflammation in IL-10 deficient mice promotes the development of 
invasive carcinoma by synthesizing the genotoxin colibactin [143]. Colibactin causes DNA double-
strand breaks and incomplete DNA repair resulting in genomic instability [229]. 
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But microbiota can as well confer protection against colorectal cancer and prevent carcinogenesis. 
The microbial metabolite butyrate activates the receptor GPR109a that triggers production of 
cytoprotective IL-18 and induces differentiation of Treg cells through IL-10, while inhibiting formation 
of pro-inflammatory Th17 cells [230]. Probiotics such as bifidobacteria and lactobacilli create a 
favorable microenvironment that decreases not only inflammatory conditions but also the 
emergence of colorectal cancer. Especially in combination with prebiotics, Bifidobacterium and 
Lactobacillus genera were shown to reduce aberrant crypt foci occurrence in mice and in rats [226]. 
Clostridium difficile-associated diarrhea 
C. difficile is a spore-forming strictly anaerobic gram-positive bacterium that is often found in 
asymptomatic subjects, including more than 50% of children and 15% of healthy adults. The mere 
presence of toxicogenic C. difficile in a host is not a predictive marker for intestinal inflammation 
[231]. Progression to disease requires in fact vegetative growth of C. difficile and secretion of toxins 
such as the TcdA and TcdB enzymes, which are glycosyltransferases modifying cytoplasmic Rho 
GTPases, thereby impairing cytoskeleton integrity [232]. The activity of TcdA and TcdB toxins is 
sufficient to trigger disease when released in the host intestinal tract [233]. The germination of C. 
difficile is facilitated by some bile acids found in the duodenum, such as taurocholate and 
deoxycholate [234]. The gut microbiota plays an essential role in suppressing the vegetative growth 
of C. difficile in asymptomatic subjects, although the mechanisms of this inhibition remain unclear. A 
group of microbes may prevent the proliferation of C. difficile by exhausting nutrients essential for its 
growth. Carbohydrates, such as N-acetylglucosamine and Neu5Ac derived from intestinal mucins, are 
important nutrients supporting the growth of C. difficile [84]. These carbohydrates are preferentially 
metabolized by other gut microbes, thereby limiting the expansion of C. difficile and consequently 
disease development [235]. Besides sequestering nutrients away from C. difficile, some microbes 
transform bile acids, thereby reducing the rate of germination of clostridial spores in the gut [236]. 
The importance of gut microbes in mediating resistance to C. difficile growth is illustrated by the 
impact of antibiotics on promoting C. difficile-associated diarrhea. The study of C. difficile infection in 
conjunction with antibiotic treatments linked the expansion of C. difficile to decreased 
Lachnospiraceae and increased Enterobacteriaceae levels in animal models [237-239]. Elevated levels 
of Enterobacteriaceae were also noted in elderly human subjects presenting with C. difficile-
associated diarrhea [240, 241]. Finally, the astonishing success of fecal microbial transplantation 
definitively demonstrated the role of the gut microbiota at keeping C. difficile at bay. The treatment 
of patients with refractory C. difficile infection by infusion with microbiota derived from healthy 
donors cured more than 90% of cases, whereas the traditional treatment with vancomycin only 
improved 30% of cases [242]. The incidence of C. difficile infection increases with age, probably 
reflecting the progressive decreased microbial diversity and the loss of microbes conferring 
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resistance to C. difficile. As recently presented, the expansion of C. difficile may be related to 
decreased bacteriocins secreted by bacteria that normally keep the pathogen at bay in asymptomatic 
subjects [187]. The identification of bacteriocins targeting C. difficile would represent a valuable 
alternative or at least a complementary approach to fecal microbial transplantation.      
Concluding remarks  
The gut microbiota is an inherent component of animal physiology that reacts to internal and 
environmental changes, while playing important roles in regulating multiple host functions. As 
outlined in the present review, the contribution of dysbiosis to diseases is undisputed, but the 
mechanisms in play and the assignment of truly pathogenic microbes often remains circumstantial, if 
not speculative. The recent development of high-throughput sequencing techniques linked to the 
establishment of reliable microbial 16S rRNA sequence databases resulted in an explosion of reports 
documenting the importance of the gut microbiota in regulating health and disease. Despite the 
wealth of information unraveled through past studies, the taxonomic identification of intestinal 
bacteria only clarifies a single variable of the equation explaining gut ecology. Metagenomic 
approaches documenting the global genetic diversity of the intestinal ecosystem are gaining 
momentum as sequencing technologies and bioinformatic analysis constantly improve [243]. The 
determination of biochemical parameters beyond the classical survey of SCFA profiles adds further 
dimensions to the characterization of metabolic pathways at play in microbial communities [244]. 
Finally, the integration of all data through heuristic algorithms [245] will not only facilitate the 
interpretation of experimental models but also enable the recognition of novel mutualistic networks 
among the gut microbiota. The comprehensive appreciation of gut ecology will allow a better control 
of intestinal dysbiosis and thereby lead to a significant health improvement across a broad range of 
inflammatory and metabolic conditions afflicting our modern society.  
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Figure Legends 
Figure 1. Factors contributing to intestinal dysbiosis. The gut microbiota is subject to natural 
variations induced by the changing supply of nutrients, drugs, the immune system, and the intestinal 
mucosa. The action of stress factors such as oxidative stress, the induction of bacteriophages, and 
secretion of bacteriocins amplify the changes in microbial composition leading to decreased diversity 
and outgrowth of specific bacterial taxa.  
Figure 2. Consequences of nutritionally induced imbalance between Firmicutes and Bacteroidetes. 
Obesity, high dietary fat and sugar intake and an enlarged bile acid pool decrease the Bacteroidetes 
to Firmicutes ratio. Changes in this ratio affect chronic inflammation, and metabolic changes related 
to energy supply to colonocytes, lipogenesis, gluconeogenesis, insulin sensitivity and thereby glucose 
tolerance. Bacterial LPS (A), SCFA (B), increased monosaccharide uptake (C) and secondary bile 
metabolisms (D) are key mediators of such metabolic adaptations. ANGPTL4, angiopoietin-like factor 
IV; FXR, farnesoid X receptor; TGR5, G-protein-coupled bile acid receptor; SCFA, short chain fatty 
acid; GPR43/GPR41, G-protein-coupled receptors 43/41; LPS, lipopolysaccharide; ChREBP, 
carbohydrate response element-binding protein; SREBP1c, sterol regulatory element-binding protein 
1c. 
Figure 3. Mechanisms of immune regulation of the gut microbiota. Elements of the inflammasome 
(A), the innate (B, C) and adaptive immune systems (D) control the gut microbiota composition. 
Interplay between cytokines, immune cells, bacterial groups, and the intestinal environment in 
affecting inflammation, tissue repair, and secretion of antimicrobial peptides. TLR5, Toll-like receptor 
5; NOD2, nucleotide oligomerization domain 2 receptor; NLRP6, NOD-like receptor family pyrin 
domain containing 6; IgA, immunoglobulin A; IL, interleukin; DSS, dextran sulfate sodium; SFB, 
segmented filamentous bacteria; Th17 cells, T helper 17 cells; Treg cells, regulatory T cells; TGF-β, 
transforming growth factor beta. 
 
